A good start to the week and it should continue the momentum for the sector. While I think we still can move on the news, it is also the case that the sector has had a nice run recently. Nothing goes up (or down forever) and the longer the run, the better the news has […]
August 4th Biotech Update
Are we finally starting to see the wheels of M&A loosen? Perhaps. We got some this morning as well as a new rumor. It is enough to move the sector (at least a little). We are definitely in a different spot as the news is actually moving the sector higher. It was not that long […]
August 3rd Biotech Update
We started the week at the bottom of the range and within three days we are at the top of the range. I find days like this a little tough to judge. Big positive moves like this make it feel like there is very strong momentum but when they smack against the top of a […]
The XBI – A Short Term Outlook
Many are asking if the XBI is done with the bounce and will drop back to test the 52-week low around $61, or it is still in a consolidation mode and will continue the recovery and move upward again! Here is my outlook for the biotech sector these days. The XBI used as a leading […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
